Last edition
News about "Moebius Medical "
Sun Pharma and Moebius Medical Receive FTD for MM-II for Treatment of Osteoarthritis Knee Pain
Sun Pharma and Moebius Medical have announced that the US Food and Drug Administration (FDA) has granted Fast Track designation (FTD) to MM-II (Large Liposomes of DPPC and DMPC) for the treatment of osteoarthritis knee pain.
Moebius Medical | 07/09/2024 | By Aishwarya
Sun Pharmaceutical Industries and Moebius Medical have presented data demonstrating the durability of pain relief achieved in symptomatic knee OA patients through 26 weeks post injection of MM-II.
Moebius Medical | 15/06/2024 | By Aishwarya | 293
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy